Price T Rowe Associates Inc Atea Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 70,001 shares of AVIR stock, worth $227,503. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,001

Previous 66,660 5.01%

Holding current value

$227,503

Previous $221,000 6.33%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.17 - $4.02 $10,590 - $13,430	3,341 Added 5.01%	70,001 $235,000
Q2 2024 Aug 14, 2024	SELL	$3.31 - $4.04 $1,578 - $1,927	-477 Reduced 0.71%	66,660 $221,000
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $36,981 - $54,574	11,968 Added 21.69%	67,137 $272,000
Q4 2023 Feb 14, 2024	BUY	$2.8 - $3.35 $36,195 - $43,305	12,927 Added 30.6%	55,169 $169,000
Q3 2023 Nov 14, 2023	BUY	$3.0 - $3.79 $3,030 - $3,827	1,010 Added 2.45%	42,242 $127,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $4,776 - $7,529	1,488 Added 3.74%	41,232 $155,000
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $32,793 - $54,327	10,931 Added 37.94%	39,744 $134,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $5,185 - $7,354	1,192 Added 4.32%	28,813 $139,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $24,924 - $39,906	4,540 Added 19.67%	27,621 $158,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $2.25 Million - $3.46 Million	-422,879 Reduced 94.82%	23,081 $164,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $181,747 - $303,683	33,045 Added 8.0%	445,960 $3.22 Million
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $8.31 Million - $48.3 Million	-1,083,050 Reduced 72.4%	412,915 $3.69 Million
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $4.17 Million - $6.85 Million	-195,517 Reduced 11.56%	1,495,965 $52.4 Million
Q2 2021 Aug 16, 2021	SELL	$19.22 - $59.08 $16.7 Million - $51.4 Million	-869,893 Reduced 33.96%	1,691,482 $36.3 Million
Q1 2021 May 17, 2021	BUY	$41.42 - $88.44 $1.8 Million - $3.84 Million	43,398 Added 1.72%	2,561,375 $154 Million
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $66.4 Million - $105 Million	2,517,977 New	2,517,977 $102 Million

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Atea Pharmaceuticals, Inc. Transaction History